Search
Evogene Ltd
EVGNAdd to Watchlist
0.492USD
-0.028-5.46%
Close 07-28 16:00（ET）Quotes delayed by 15 min
5.12MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-28The current earnings forecast score of Evogene Ltd is 8.00, ranking 168 out of 385 in the Biotechnology & Medical Research industry. The average price target is 2.50, with a high of 2.50 and a low of 2.50.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
2.150
Target Price
+296.31%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Evogene Ltd
EVGN
1
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Evogene Ltd's expected revenue for the next quarter?
Evogene Ltd's expected revenue is 325.00K.
What is Evogene Ltd's price target?
Analysts forecast that Evogene Ltd's price target is USD 2.50, with the highest forecast at USD 2.50 and the lowest forecast at USD 2.50.
How have Evogene LtdEVGN's recent earnings per share performed?
The market expectation was USD -0.60, while Evogene LtdEVGN's earnings per share (EPS) for the previous quarter was USD -0.61. EPS for the next quarter is expected at USD -0.27.
What is the analyst rating for Evogene Ltd?
Based on the ratings of Evogene Ltd's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.